SARS-CoV-2-Specific Antibody Profiles Distinguish Patients with Moderate from Severe COVID-19
De Campos Mata, L.; Pinero, J.; Tejedor Vaquero, S.; Tacho-Pinot, R.; Kuksin, M.; Arrieta Aldea, I.; Rodrigo Melero, N.; Carolis, C.; Furlong, L.; Cerutti, A.; Villar-Garcia, J.; Magri, G.
Show abstract
The production of SARS-CoV-2-specific neutralizing antibodies is widely considered as a key mechanism for COVID-19 resolution and protection. However, beyond their protective function, antibodies to SARS-CoV-2 may also participate in disease pathogenesis. To explore the potential relationship between virus-specific humoral responses and COVID-19 immunopathology, we measured serum antibody classes and subclasses to the receptor-binding domain of the SARS-CoV-2 spike protein and the nucleoprotein in a cohort of hospitalized COVID-19 patients with moderate to severe disease. We found that RBD-specific IgG1 and IgG3 dominated the humoral response to SARS-CoV-2, were more abundant in severe patients, and positively correlated with several clinical parameters of inflammation. In contrast, a virus-specific IgA2 response skewed toward RBD rather than NP associated with a more favorable clinical course. Interestingly, RBD-dominant IgA2 responses were mostly detected in patients with gastrointestinal symptoms, suggesting the possible involvement of intrinsically tolerogenic gut immune pathways in the attenuation of virus-induced inflammation and disease resolution.
Matching journals
The top 9 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Occurrence of COVID-19 symptoms during SARS-CoV-2 infection defines waning of humoral immunity 96%
- sMAdCAM:IL-6 (sMIL Index): A novel signature associated with COVID-19 disease progression and development of anti-SARS-CoV-2 antibodies 95%
- Long-term systemic and mucosal SARS-CoV-2 IgA response and its association with persistent smell and taste disorders 95%
Similar papers in this journal
Similar papers in this journal
- Combination therapy with oral antiviral and anti-inflammatory drugs improves the efficacy of delayed treatment in severe COVID-19 94%
- Pathogenic and transcriptomic differences of emerging SARS-CoV-2 variants in the Syrian golden hamster model 93%
- Anti-SARS-CoV-2 Antibodies Persist for up to 13 Months and Reduce Risk of Reinfection 93%
Similar papers in this journal
- Carbohydrate-Binding Protein from Stinging Nettle as Fusion Inhibitor for SARS-CoV-2 Variants of Concern 93%
- Effective prophylaxis of COVID-19 in rhesus macaques using a combination of two parentally-administered SARS-CoV-2 neutralizing antibodies 92%
- The Requirement For US28 During Cytomegalovirus Latency Is Independent Of US27 And US29 Gene Expression 92%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.